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Abstract While studies have shown that use of post-
menopausal hormone therapy with estrogen and progesto-
gen (EPT) increases mammographic density, aspects of this
association remain unclear. We examined whether mam-
mographic density differed by type of hormone therapy
(HT) used, dose, duration of use, time since last use, and
whether the effects are modified by age and body mass
index (BMI). Using a cross-sectional design, we recruited
2,424 postmenopausal women aged 50–69 years partici-
pating in the Norwegian Breast Cancer Screening Program.
Mammographic density was assessed with a computer-
assisted method, and we estimated mean absolute and
percent mammographic density through multiple linear
regression, and adjusting for possible confounders. Mam-
mographic density was higher among current HT users
(percent density: 22.6%; 95% CI: 22.1–23.2%) than among
former (17.7%; 17.2–18.2%) or never users (16.3%;
15.7–16.8%). The highest density was seen in current EPT
users of high-dose norethisterone acetate (NETA) regimens
who had a percent density of 26.2% (24.3–28.1%). Results
differed when considering the combined effect of age and
BMI. The effect of EPT on mammographic density was
modified by age and BMI, with no apparent association
among the youngest women (aged 50–55) with the highest
BMI (BMI C 26). A higher mammographic density was
found in EPT users compared to never HT users, particu-
larly in women using high-dose NETA regimens. Age and
BMI modified the association between EPT use and
mammographic density.
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Introduction
Mammographic density refers to the white (radiodense)
areas on a mammogram and reflects the amount of
stroma and epithelium in the breast, as opposed to fat that
appears dark (radiolucent) [1]. High mammographic
density is a strong risk factor for breast cancer and
confers a four- to fivefold increase in risk [1, 2]. Mam-
mographic density is highly related to screening sensi-
tivity, with higher mammographic density inversely
associated with poorer sensitivity [3, 4]. Hence, factors
increasing mammographic density are expected to
decrease mammographic sensitivity and, subsequently,
the effectiveness of mammographic screening. It is
therefore important to identify factors associated with
mammographic density.
Mammographic density declines after menopause [5,
6], suggesting that hormonal factors are important deter-
minants of mammographic density. It has been consis-
tently shown that combined estrogen–progestogen therapy
(EPT) increases mammographic density [7–18]. However,
certain aspects of this association need to be further
clarified. While mammographic density is clearly higher
in users of EPT compared to never users [7–9, 11, 12, 15,
17, 18], the effect of estrogen-alone regimens (ET)
remains unclear [8–10, 12, 15, 17, 18]. Furthermore, it is
not clear whether different types of EPT have different
effects on mammographic density. For example, noreth-
isterone acetate (NETA) regimens have been shown to be
associated with a higher risk of breast cancer than other
types of EPT [19], but only a limited number of studies
have examined whether this type of EPT affects mam-
mographic density differently than other types [7, 15].
Furthermore, few studies have investigated mammo-
graphic density in relation to duration of hormone therapy
(HT) use, or the time since stopping HT, and the results
have been inconclusive [7, 14, 15].
Postmenopausal EPT is a recognized risk factor for
breast cancer [20–23]. Several factors, important in the
etiology of breast cancer, are also determinants of
mammographic density. Studies have consistently shown
that mammographic density declines with increasing age
and body mass index (BMI) [9, 24]. Although there is
evidence that age and BMI may separately modify the
effect of HT on mammographic density [10–12, 16, 18],
it is not clear how the two factors combined affect
density.
In this article, we used a cross-sectional design and
recruited women through the Norwegian Breast Cancer
Screening Program (NBCSP), in order to examine
the association between HT use and mammographic
density.
Materials and methods
Participants and study design
All Norwegian women aged 50–69 years are biennially
invited by the NBCSP to undergo a bilateral two-view
mammogram. We recruited women to our cross-sectional
study through the NBCSP. All women invited to participate
in the screening program during specific weeks of 2004 in
three selected counties (Oslo, Akershus, and Hordaland)
were invited to our study. We sent a study invitation, a
consent form, and a questionnaire with the invitation to
attend the NBCSP. Women were asked to bring the com-
pleted informed consent and questionnaire with them on the
day of their appointment. All women who returned a signed
informed consent were eligible to participate. A total of
17,050 women were invited to participate in our study,
among those 12,056 (70.7%) attended the screening. The
project was approved by the regional ethics committee and
the Norwegian Data Inspectorate.
The study questionnaire included questions on anthro-
pometric measurements, age at menarche, reproductive
history, history of oral contraceptive and postmenopausal
HT use, family history of breast cancer, and demographic
history. Among the 12,056 eligible women, 7,941 (66%)
returned the questionnaire and a signed informed consent.
A dietary questionnaire was sent to 7,174 women who had
agreed to complete it. We requested mammograms of the
women who had returned a completed dietary question-
naire and had undergone a mammogram in 2004
(N = 3,180), and we obtained mammograms for 2,876 of
them.
Mammographic density assessment
Left breast cranio-caudal mammograms were digitized
using a Kodak Lumisys 85 scanner (Kodak, Rochester,
New York, USA). Mammographic density was assessed on
the digital images using the University of Southern Cali-
fornia Madena computer-based method, which has previ-
ously been described and validated [25]. In brief, the
Madena program works as follows: A reader pulls up the
mammogram on a computer screen and first defines the
total breast area using a special outlining tool; the software
then estimates the total number of pixels in the breast (total
breast area). Next, the density is assessed as follows: The
reader defines a region of interest in the breast that contains
all the densities, but that excludes the pectoralis muscle,
prominent veins, fibrous strands, and other light artifacts.
The reader uses a tinting tool to apply a yellow tint to the
area within the region of interest considered to represent
densities. The software estimates the number of tinted
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pixels within the region of interest (absolute density). The
percent density is the absolute density area divided by the
total breast area (multiplied by 100). The density assess-
ments were performed by an experienced reader (GU),
whereas the breast area measurements were taken by MH
(after training by GU). The readers were blinded to all
subject characteristics.
Exclusions
Women with previous history of breast (N = 12) or ovar-
ian (N = 5) cancers were excluded. Fifteen women aged
less than 50 or more than 69 years at recruitment were
excluded. This report only considered postmenopausal
women, and we therefore excluded 417 pre- or perimeno-
pausal women. Women were considered postmenopausal if
they had reported (a) complete cessation of menstruation
for a period of at least 6 months, (b) previous bilateral
oophorectomy, (c) hysterectomy without bilateral oopho-
rectomy, or (d) used HT before menstruation had stopped.
This report primarily investigates the effect of EPT and/or
ET use on mammographic density; hence, 3 women
exclusively using progestogen were excluded. In the
present report, 2,424 women were included.
Statistical analyses
We used multiple linear regression models to calculate
least square means of percent and absolute density
according to HT use. The mammographic density variables
were treated in a continuous manner, without any trans-
formations, as the models’ residuals satisfied the normality
and homoscedasticity assumptions [26]. We assessed mean
mammographic density in never, former, and current HT
users and examined the effect of duration of use, as well as
time since cessation of HT use, and type of HT (EPT vs.
ET regimens, low and high EPT doses, and NETA users or
not). Women were considered as current users if they had
been using the specified HT for more than 3 months. Users
of low-dose NETA regimens were women using 1 mg of
estradiol and 0.5 mg of NETA (Activelle), and high-dose
NETA preparations were 2 mg of estradiol and 1 mg of
NETA (Kliogest). Ascertainment of HT use was done
with two questions asking about (1) ever use of HT—with
a proposed list of HT preparations—and (2) current use of
HT. Therefore, a woman could have used more than one
type of HT, and, in particular, she could have used both ET
and EPT, or NETA and non-NETA regimens in her life-
time. Previous and current use of HT was entered in the
model simultaneously to account for the fact that women
could have used different HT preparations in their lifetime.
HT use was also examined constructing variables that
measured the combined use of different HT types
considering all possible combinations of use. Models were
adjusted for confounders selected a priori: age at screening
(continuous), BMI (in kg/m2, continuous), number of chil-
dren (continuous), age at first childbirth (continuous), first-
degree family history of breast cancer (categorical: yes/no),
and number of years spent in school (continuous). The
categorical variables for HT use and breast cancer family
history were entered in the model constructed as dummy
variables, with never HT use representing the reference
category for HT use, and no breast cancer in a first-degree
relative as a reference category for breast cancer family
history. We also considered a number of other potential
confounders, such as age at menarche, age and type of
menopause, oral contraceptive use, consumption of alcohol,
and physical activity. However, as adjusting for these
variables influenced the estimates by less than 5%, they
were not included in the final model. We investigated
possible effect modification by age and BMI on the asso-
ciation between EPT use and mammographic density by
stratifying analyses by age and BMI. We used v2 tests for
heterogeneity and trend to evaluate differences in estimates
of mammographic density by EPT use. Interaction by age
and BMI, respectively, was evaluated by entering interac-
tion terms in the model, and, in each case, using a likelihood
ratio test to compare the model with an interaction term
with the model without the interaction term.
Results
Ever users of HT had a lower BMI, were more likely to
have used oral contraceptives, had fewer children, and no
first-degree relative diagnosed with breast cancer compared
to women who never used HT (Table 1).
Overall, the average percent mammographic density
was 18.2% (95% CI: 17.9–18.5%), and the average abso-
lute density was 23.5 cm2 (95% CI: 23.3–23.7 cm2)
(Table 2). Both percent and absolute density were higher in
women who reported to have ever used HT compared to
never users. When comparing current, former, and never
HT users, we found the highest mammographic density in
current HT users, followed by former users, and the lowest
densities in never HT users, with percent densities of
22.6% (22.1–23.2%), 17.7% (17.2–18.2%), and 16.3%
(15.7–16.8%), respectively. Similar results were obtained
for absolute density. Women who reported having ever
used EPT had higher percent density, with the highest
density seen in current EPT users. Women who were cur-
rently using EPT had percent density of 25.4%
(24.6–26.1%) compared to 16.3% (15.7–16.8%) in never
HT users, with similar results seen for absolute density.
Current ET users had percent density of 18.9%
(17.6–20.2%). However, mammographic density in ET
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users was higher than never HT users’ only in women who
had formerly used EPT with percent density of 22.3%
(20.3–24.3%), compared to 15.0% (13.8–16.2%) in former
users of ET. Current tibolone users had a mammographic
density similar to never HT users: 17.7% (16.5–19.0%)
compared to 16.6 (16.0–17.1%) in never users. All former
tibolone users had also used another HT type (ET or EPT);
specifically, 21 out of the 89 former users of tibolone were
also current users of another HT type, and 68 had also
formerly used another HT type. When examining the
association between duration of EPT use and mammo-
graphic density in current users, percent and absolute
densities remained the same across different strata of
duration (Table 2). When considering total duration in ever
EPT users, higher percent and absolute densities were seen
with higher total duration of EPT use. Women who had
used HT for 8 or more years had percent densities of 21.6%
(20.7–22.6%), compared to 19.6% (18.5–20.6%) in women
who had used HT for 4 years or less (p for trend = 0.01).
We also examined the association between time since last
EPT use and mammographic density and found different
results for percent and absolute densities (Table 2). While
we found significantly lower percent density with higher
numbers of years since stopping EPT (p for trend = 0.03),
no statistically significant association was found between
absolute density and years since stopping EPT (p for
trend = 0.17).
Overall, lower percent mammographic density was seen
with lower age and BMI (Table 3). In statistical analyses
stratified by BMI or age, we found higher densities with
EPT use in all categories of BMI or age. However, when
stratifying the analyses by both age and BMI, no association
between EPT use and percent density was found in younger
women (aged B 55) with a higher BMI (BMI C 26).
Among these women, the percent density was 12.3%
(11.2–13.4%) in never HT users and 12.0% (10.5–13.2%) in
ever EPT users. In all other categories of age and BMI
considered, percent density was statistically higher in ever
EPT users compared to never HT users. We found an
interaction between age and EPT use for absolute density
(P = 0.01). However, there was no statistically significant
interaction between age and never/ever EPT use with
respect to percent density (P = 0.10). For BMI, there was a
statistically significant interaction for percent density
(P = 0.03) and no statistically significant interaction for
absolute density (P = 0.56).
Percent density differed according to the type of EPT
regimens used (Table 4). Higher densities were seen in
ever NETA regimen users compared to ever users of other
EPT types. Estimates of percent density were 20.7%
(20.2–21.1%) in ever NETA regimen users and 19.6%
(18.3–20.8%) in ever users of other types of regimens.
Most current users of non-NETA regimens (7 out of 12)
were former users of NETA preparations. Lower percent
densities were seen in users of low doses of NETA EPT
regimens (1 mg of estradiol, 0.5 mg of NETA, Activelle)
compared to high-dose (2 mg of estradiol, 1 mg of NETA,
Kliogest) users. Among current NETA users, the esti-
mates of percent density were 24.6 (23.7–25.5%) and
26.2% (24.3–28.1%) in low- and high-dose NETA regimen
users, respectively. However, differences in mammo-
graphic density between high- and low-dose NETA regi-
men users did not reach statistical significance.
Table 1 Characteristics of never and ever users of hormone therapy
Hormone therapy use
Never users Ever users
Hormone therapy use (N) 1,053 1,371
Age at screening (mean, ±SD) 58.2 (±5.8) 58.6 (±5.0)
Body mass index (N, %)
B23 320 (31.1) 424 (31.7)
[23, B26 322 (31.3) 486 (36.3)
[26 386 (37.5) 427 (31.9)
Years of school (N, %)
B9 181 (17.4) 209 (15.4)
10–12 373 (36.0) 463 (34.2)
13–16 307 (29.6) 443 (32.7)
17? 176 (17.0) 240 (17.7)
Age at menarche (in years, N, %)
\12 115 (11.0) 137 (10.1)
12–14 788 (75.3) 986 (72.6)
15? 143 (13.7) 235 (17.3)
Oral contraceptive use (N, %)
No 590 (58.0) 588 (45.6)
Yes 427 (42.0) 701 (54.4)
Age at first child (in years, mean,
±SD)
22.1(± 8.2) 22.4 (± 7.5)
Number of children (N, %)
0 100 (9.5) 115 (8.4)
1 108 (10.3) 161 (11.7)
2–3 702 (66.7) 999 (72.9)
4? 143 (13.6) 96 (7.0)
Age at menopause (in years, mean,
±SD)
49.5 (±5.1) 49.2 (±5.5)
Type of menopause (N, %)
Natural 872 (89.2) 748 (62.4)
Use of hormone therapy 0 (0) 230 (19.2)
Surgical menopause 101 (10.3) 217 (18.1)
Radiotherapy or chemotherapy 4 (0.4) 3 (0.2)
First-degree family history of breast cancer (N, %)
None 923 (87.6) 1251 (91.2)
At least one fist-degree relative 130 (12.3) 120 (8.7)
Due to missing values, numbers in subcategories do not add up
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Table 2 Percent and absolute mammographic density according to hormone therapy use, duration of use, and time since last use
Percent density Absolute density
% (95% CI) cm2 (95% CI)
Na Unadjusted Adjustedb Unadjusted Adjustedb
Overall 2424 18.3 (17.6–18.9) 18.2 (17.9–18.5) 23.4 (22.6–24.2) 23.5 (23.3–23.7)
Hormone therapy use
Never 1053 16.4 (15.4–17.3) 16.3 (15.7–16.8) 21.1 (19.9–22.3) 21.0 (20.6–21.3)
Ever 1371 19.8 (18.9–20.6) 19.6 (19.3–20.0) 25.2 (24.0–26.3) 25.4 (25.1–25.7)
Former 842 18.1 (17.0–19.1) 17.7 (17.2–18.2) 23.4 (22.0–24.8) 23.6 (23.3–23.9)
Current 529 22.5 (21.0–23.9) 22.6 (22.1–23.2) 28.1 (26.2–30.0) 28.2 (27.8–28.6)
Never 1053 16.4 (15.4–17.3) 16.3 (15.7–16.8) 21.1 (19.9–22.3) 21.0 (20.6–21.3)
Former ET/No EPT 118 15.4 (12.6–18.1) 15.0 (13.8–16.2) 22.4 (18.6–26.3) 22.7 (21.9–23.6)
Former EPTd/No ET 609 18.8 (17.5–20.0) 18.4 (17.9–19.0) 23.9 (22.3–25.5) 24.1 (23.7––24.4)
Former EPT/Former ET 80 16.3 (13.2–19.5) 16.3 (14.8–17.8) 21.1 (17.3–24.8) 22.1 (21.1–23.1)
Current ET/No EPT 94 17.7 (14.6–20.8) 17.4 (15.8–19.0) 22.4 (18.6–26.2) 22.6 (21.6–23.7)
Current ET/Former EPT 42 21.9 (17.7–26.0) 22.3 (20.3–24.3) 27.7 (21.1–34.3) 27.1 (25.7–28.5)
Current EPT/No ET 274 25.1 (23.0–27.1) 25.4 (24.7–26.2) 30.2 (27.6–32.8) 30.5 (30.0–31.0)
Current EPT/Former ET 22 25.1 (16.8–33.5) 23.7 (20.7–26.8) 34.2 (23.9–44.4) 31.9 (29.8–34.0)
Never 16.4 (15.4–17.3) 16.6 (16.0–17.1) 21.1 (19.9–22.3) 21.4 (21.1–21.8)
Former ET 220 16.7 (14.6–18.8) 16.4 (15.4–17.4) 23.4 (20.4–24.8) 23.5 (22.3–24.2)
Former tibolone 89 24.9 (20.4–29.4) 25.6 (24.2–27.1) 28.5 (24.1–33.0) 29.4 (28.4–30.4)
Former EPT 731 18.7 (17.6–19.8) 18.4 (17.9–18.9) 23.8 (22.3–25.3) 24.0 (23.7–24.4)
Current ET 136 19.0 (16.5–21.5) 18.9 (17.6–20.2) 24.1 (20.7–27.4) 24.0 (23.1–24.9)
Current tibolone 83 17.2 (13.8–20.5) 17.7 (16.5–19.0) 23.3 (18.3–28.4) 24.5 (23.7–25.4)
Current EPT 296 25.1 (23.1–27.1) 25.4 (24.6–26.1) 30.5 (28.0–33.0) 30.6 (30.3–31.1)
Duration of hormone therapy use (in years, in EPT users)f
In current users
\2 86 25.7 (22.3–29.0) 25.6 (23.7–27.4) 29.7 (25.8–33.6) 29.7 (28.6–30.3)
2–3 82 22.5 (18.9–26.2) 22.7 (21.0–24.5) 29.0 (24.1–34.0) 29.0 (28.4–29.5)
4? 110 25.9 (22.4–29.3) 26.4 (24.9–28.0) 31.7 (27.1–36.2) 32.0 (31.6–32.5)
p(trend) = 0.43 p(trend) = 0.56
Total duration of hormone therapy use (in years, in ever EPT users)
\4 231 19.0 (17.0–20.7) 19.6 (18.5–20.6) 23.7 (21.4–26.0) 24.2 (23.6–24.8)
4–7 289 21.8 (19.8–23.7) 21.7 (20.7–22.6) 26.9 (24.4–29.5) 27.0 (26.5–27.5)
8? 260 21.7 (19.6–23.7) 21.6 (20.7–22.6) 27.6 (24.7–30.4) 28.0 (27.5–28.5)
p(trend) = 0.01 p(trend) = 0.01
Time since last hormone therapy use (in years, in former EPT users)
B1.5 158 20.0 (17.4–22.5) 19.5 (18.5–20.5) 24.6 (21.3–27.8) 24.5 (24.0–25.1)
[1.5–3 166 18.4 (16.2–20.7) 18.8 (17.5–19.8) 23.4 (20.6–26.2) 24.5 (23.9–25.1)
[3 149 15.2 (13.1–17.3) 14.3 (13.2–15.4) 21.2 (18.1–24.3) 20.5 (19.8–21.1)
p(trend) = 0.03 p(trend) = 0.17
a Due to missing values, numbers in subcategories do not add up
b Adjusted for age at screening (continuous), body mass index (continuous), number of children (continuous), age at first childbirth (continuous),
first-degree family history of breast cancer (yes/no), and number of years spent at school (\6, 7–9, 10–11, 12, 13–14, 15–16, 17?)
c ET estrogen-only hormone therapy
d EPT estrogen and progestogen therapy
f The analyses were adjusted for use of ET further to the above mentioned variables (no ET use, former ET user, and current ET user)
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Discussion
Ever users of postmenopausal HT had higher percent and
absolute mammographic densities compared to never users,
with higher densities found in EPT users. The difference
observed between users and nonusers of EPT was modified
by age and BMI, with no statistical association between
EPT use and mammographic density seen in younger
women (aged 50–55), with a higher BMI (BMI C 26).
Our results are consistent with the published literature
[8–12, 17]. Previous studies have also reported higher
mammographic density among EPT users compared to ET
users [9–12, 17, 18]. Mammographic density is a strong
risk factor for breast cancer [1, 2], and the use of EPT is a
recognized risk factor for breast cancer. Studies investi-
gating the relationship between HT use and breast cancer
risk reported similar results with higher breast cancer risk
associated with the use of EPT than with ET [21, 23, 27].
However, while studies have consistently showed that EPT
use is associated with higher densities than ET, results on
whether ET users have a higher mammographic density
than never HT users are more contradictory [8–10, 12, 15,
17, 18]. Several studies have examined the effect of HT
type on mammographic density (or breast cancer risk)
without accounting for the possible use of different prep-
arations in a woman’s life. This may explain the differ-
ences in results seen in the published literature. In our
study, we have only observed higher densities in ET users
compared to never HT users in women who have also used
EPT preparations at one point in their life.
Age and BMI are strong determinants of mammographic
density; mammographic density declines with increasing
age and BMI [9, 24]. When stratifying the analyses by age
and BMI, no statistical association between EPT use and
mammographic density was found in women aged
50–55 years with a BMI of 26 and greater. To our knowl-
edge, no previous study has examined the combined effect
of both age and BMI on the association between mammo-
graphic density and HT use. Studies examining the possible
modifying effect by age have reported no association
between HT use and mammographic density in women
aged 55 or less [10–12, 16, 18]. Two studies examining HT
use and mammographic density reported no interaction by
BMI [8, 16]. Our results suggest that epidemiological
studies investigating the association between mammo-
graphic density and EPT should consider both age and BMI
as possible effect modificators. These results may indicate
that a woman’s age and BMI should be considered when
deciding whether to prescribe HT. We cannot rule out that
the differing results seen when stratifying by both age and
BMI are due to chance. More studies are needed to inves-
tigate the possible modifying effect of age and BMI on the
association between EPT use and mammographic density.
Studies investigating HT use and breast cancer risk have
shown that the increase in breast cancer risk observed in
current HT users is not seen in the past HT users [20, 21].
Consistent with these studies, we found the highest mam-
mography density in current users, followed by former and
never users. Furthermore, our results suggest that percent
mammographic density declines with years since last EPT
use, with women who stopped using EPT more than
3 years ago having percent density similar to never users.
Epidemiological studies have also investigated the effect of
short-term HT cessation on mammographic density [28–
30]: One observational study mentioned no effect [29] and
another one [30] and a clinical trial [28] reported reduced
mammographic density after stopping use of postmeno-
pausal HT. The reduction in density was reported following
cessations for 2 weeks [30] and 1 or 2 months [28]. Our
data showed that while percent mammographic density was
lower with higher time since last EPT use, no association
was found for absolute density. It is possible that it is the
breast area, rather than the dense area, that changed. We
examined breast area according to time since last use and
found average breast areas of 141.4 cm2 (135.5–147.3),
1,492 cm2 (142.6–155.8), and 163.8 cm2 (157.0–170.5) for
women stopping within the past 2 years, for more than
2 years and up to 4 years, and for more than 4 years,
respectively (p for trend = 0.08).
A strength of this study is that women completed the
study questionnaire ascertaining covariates of interest
before coming to mammographic screening. Further,
women are usually not aware what their mammographic
density is as this is not a variable that is typically reported
by radiologists in Norway. Thus, chances of recall bias are
minimal. Furthermore, previous and current use of HT was
ascertained allowing to adjust analyses for the use of dif-
ferent HT type in a woman’s lifetime.
One weakness of this study is that mammographic
density was measured only once and relied on cross-sec-
tional mean differences between the study groups, rather
than changes in density following start of HT use. How-
ever, our results are consistent with both observational
studies [6, 9, 12, 13, 17, 31] and clinical trials [8, 10, 11]
that have examined changes in mammographic density
with postmenopausal HT use and that have consistently
reported higher mammographic density in EPT users than
in never users.
The evidence published to date indicates that it is pos-
sible that use of postmenopausal EPT counteracts the
beneficial effect of menopause on mammographic density
[6]. During menopause, levels of estrogen decrease leading
to a decline in epithelial cell proliferation rates, a reduction
in stromal elements, and fatty replacement [32]. Exogenous
hormone use, such as HT, may reverse this effect by
increasing hormone level. McCormack et al. [6] have
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Table 3 Percent mammographic density according to the use of combined estrogen–progestogen therapy (EPT) by tertiles of body mass index
and age at screening
Percent density (number of womena and % (95% CI)b
Stratification by body mass index (BMI)
B23 [23–\26 C26
Overall 648 26.4 (25.9–26.8) 711 18.8 (18.4–19.2) 674 10.3 (10.0–10.5)
Never used HTc 320 24.6 (24.0–25.2) 322 16.8 (16.2–17.3) 386 8.9 (8.6–9.3)
Ever EPTd users 328 28.1 (27.5–28.7) 389 20.4 (20.0–20.8) 288 12.0 (11.7–12.3)
Never used HT 320 24.6 (24.0–25.2) 322 16.8 (16.3–17.3) 386 8.9 (8.6–9.3)
Former EPT users 212 25.8 (25.1–26.5) 282 18.8 (18.3–19.3) 219 11.4 (11.1–11.8)
Current EPT users 116 32.0 (31.0–33.0) 107 24.6 (23.8–25.3) 69 14.1 (13.5–14.6)
p(heterogeneity) \ 0.01 p(heterogeneity) \ 0.01 p(heterogeneity) \ 0.01
Stratification by age at screening (in years)
B55 56–60 61?
Overall 685 21.3 (20.7–21.9) 671 18.9 (18.3–19.5) 714 15.1 (14.5–15.6)
Never used HT 410 20.5 (19.7–21.3) 281 16.1 (15.1–17.1) 355 11.6 (10.9–12.3)
Ever EPT users 275 22.4 (21.5–23.4) 390 20.8 (20.2–21.5) 359 18.6 (18.0–19.1)
Never used HT 410 20.5 (19.7–21.3) 281 16.1 (15.2–17.1) 355 11.6 (10.9–12.3)
Former EPT users 169 21.3 (20.1–22.5) 275 18.6 (17.8–19.4) 284 16.7 (16.0–17.3)
Current EPT users 106 24.3 (22.8–25.8) 115 25.9 (24.7–27.1) 75 25.6 (24.6–26.6)
p(heterogeneity) \ 0.01 p(heterogeneity) \ 0.01 p(heterogeneity) \ 0.01
Total duration of EPT use (in years, in tertiles specific to each age stratae)
Short duration 92 21.7 (19.9–23.5) 116 21.3 (20.0–22.5) 80 14.9 (13.3–16.5)
Middle duration 70 24.7 (22.4–26.9) 90 20.0 (18.3–21.7) 87 22.7 (21.2–24.2)
Long duration 65 22.1 (19.9–24.4) 92 22.5 (20.9–24.0) 73 20.9 (19.3–22.5)
p(trend) = 0.49 p(trend) = 0.44 p(trend) = 0.13
Stratification by age at screening and BMI
B55 years old 56–61 years old 62? years old
BMI of B23
Never used HT 141 27.4 (26.5–28.4) 73 25.9 (24.8–26.9) 103 19.5 (18.5–20.5)
Ever EPT users 94 29.2 (27.9–30.4) 115 29.5 (28.5–30.4) 118 26.0 (25.0–27.0)
p(heterogeneity) = 0.02 p(heterogeneity) \ 0.01 p(heterogeneity) \ 0.01
BMI of [23–\26
Never used HT 140 20.0 (19.4–20.5) 88 16.4 (15.4–17.4) 92 12.3 (11.5–13.2)
Ever EPT users 108 22.9 (22.3–23.6) 143 20.6 (19.8–21.3) 137 18.1 (17.4–18.8)
p(heterogeneity) \ 0.01 p(heterogeneity) \ 0.01 p(heterogeneity) \ 0.01
BMI of 26?
Never used HT 119 12.3 (11.2–13.4) 112 9.4 (8.8–9.9) 153 6.3 (5.9–6.6)
Ever EPT users 66 12.0 (10.5–13.2) 128 13.6 (13.2–14.0) 93 10.0 (9.5–10.6)
p(heterogeneity) = 0.74 p(heterogeneity) \ 0.01 p(heterogeneity) \ 0.01
Women exclusively using estrogen-alone regimens (ET) were excluded
a Due to missing values, numbers in subcategories do not add up
b Analyses were adjusted for age at screening (continuous), body mass index (continuous), number of children (continuous), age at first
childbirth (continuous), first-degree family history of breast cancer (yes/no), number of years spent at school (\6, 7–9, 10–11, 12, 13–14, 15–16,
17?), and use of ET and tibolone (nonuser, former user, and current user)
c HT hormone therapy
d EPT estrogen and progestogen therapy
e Tertiles B55 = B2, 3–5, [5; 57–60 = B4, 5–8 [ 8; 61? = B6, 7–11, 12?
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estimated that mammographic density decreases by 2.4%
(95% CI: 1.4–3.4%) during the menopausal transition and
increases by 2.4% (1.4–3.5) with the use of HT in post-
menopausal women. Thus, the total effect would be a
slightly lower density in postmenopausal HT users as
compared to premenopausal women. The association of
EPT use with percent density has been shown to be greater
among those who later developed breast cancer [33], sug-
gesting that the response of breast tissue to exogenous
hormones is to some degree predictive of the future
development of breast cancer. Furthermore, the Women’s
Health Initiative trial reported that the relationship between
EPT use and breast cancer risk appears to be mediated
through mammographic density [34]. Likewise, in data
from an international randomized clinical trial of tamoxifen
versus placebo, the risk of breast cancer was reduced only
among women who obtained a 10% or greater reduction in
mammographic density while on tamoxifen [35].
In this study, we found a higher mammographic density
in EPT users, with the highest densities seen in current users
of high-dose NETA regimens. We also showed that the
association between EPT use and mammographic density is
modified by age and BMI, where the association is apparent
in all but the youngest EPT users with a higher BMI. Our
results suggest that women’s age and BMI should be taken
into account when deciding on whether to use EPT.
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